Ra stock: buy or sell?

RARX stock price: $47.99 -0.04% At close on April 1st, 2020

Updated on:
April 1st, 2020


After topping to all time highs on Tuesday, Ra remained constant -0.04% on Wednesday to $47.99.

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States.

Should I buy Ra stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to choose your own trading plan that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

These 2 buy setups are elegible for Ra Pharmaceuticals stock right now:

Buy setupElegible
New all-time highYes
New 52 week highYes
Price crossing up 200d MANo
100d MA crossing up 200d MANo

Is Ra stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. Unfortunately, we couldn't detect any rating for RARX stock for the last 30 days.

Ra stock analysis

Daily outlook

After yesterday all time highs, Ra Pharmaceuticals remained constant to $47.99.

Ra remained steady -0.04% to $47.99 after yesterday all time highs. From a daily perspective, RARX is in a short term uptrend after plotting its last bottom ($46.34, on March 26th) higher than the previous bottom, and its last top ($48.02, on Tuesday) also over the previous top. Now trading in between its last bottom and last top RARX might consolidate in a plain range, waiting to break out over $48.02 or down under $46.34. Since price and SMA100d lines crossed up on Mar 25th, RARX climbed $2.04 (4.44%). On Tuesday, RARX hit new all time highs, pushing higher previous ATH of $47.77 recorded on Mar/25. New ATHs are usual entry points for many trading setups as there aren't higher resistences.

RARX stock chart (daily)

Weekly outlook

Ra shares stepped up 2.32% last week and marked a new all time high at $48.02.

Early October RARX price bounced up over the SMA of 40 weeks that acted as support stopping new slides.

RARX stock chart (weekly)

Ra stock price history

Ra stock went public on October 26th, 2016 with a price of $14.161. Since then, RARX stock surged a 238.90%, with a yearly average of 79.60%. If you had invested $1,000 in Ra stock in 2016, it would worth $2,389.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Ra stock historical price chart

RARX stock reached all-time highs on Tuesday with a price of $48.02.

Ra stock price target

How much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we have not found any price forecast for Ra Pharmaceuticals stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

Ra disappointed experts when it reported an Earnings per Share (EPS) of $-0.47 when the market consensus was $-0.52.
RARX earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2018, Ra Pharmaceuticals annual revenues collapsed a bloodcurdling -49.27% to $2.50 M dollars from $4.93 marked in 2016. Likewise, its earnings margin (compared to sales) plunged to -2,597.72%, that is $-64.94 million.

RARX annual Sales and Income evolution
2014$4.83 M-$-5.48 M-113.4%-
2015$4.09 M-15.24%$-13.94 M-340.6%154.62%
2016$4.93 M20.37%$-28.86 M-585.7%107.01%
2018$2.50 M-49.27%$-64.94 M-2597.7%125.00%

Quarterly financial results

Ra Pharmaceuticals reported $2.50 M in sales for 2018-Q4, a inf% improvement compared to previous quarter. Reported quarter earnings marked $-16.20 million with a profit margin of -647.80%. Profit margin stayed steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Ra sales marked an extraordinary increase and rocketed a inf%.
RARX quarterly Sales and Income evolution
2018-Q4$2.50 M-$-16.20 M-647.8%-

Ra ownership

When you are planning to buy shares of a company, it's worth to overview its ownership structure.

Ra Pharmaceuticals shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 4.03% of all shares.

Bearish positions for RARX stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Ra Pharmaceuticals:

Market cap$2.3 B
Total shares47.2 M
Float shares35.9 M
  - Institutional holdings (%)106.2%
  - Insider holdings (%)4.0%
Shares in short selling0.0%

Ra summary

Wednesday, April 1st, 2020
Day range$47.98 - $48.01
Previous close$48.01
Session gain-0.04%
Average true range$2.16
50d mov avg$46.43
100d mov avg$46.66
200d mov avg$39.47
Daily patternlt06a
Weekly pattern

Ra performance

To better understand Ra performance you must becnhmark its gains with other related stocks in same sector or industry. We compared Ra against in the following table:
RARXRa Pharmaceutical...2.37%98.55%104.13%

Ra competitors

Unfortunately, we could not find any public company that could be defined as Ra Pharmaceuticals competitor. This doesn't mean Ra Pharmaceuticals does not have any competitor in the market, it's just we could not detected it.